LOGISTIC REGRESSION AND SURVIVAL ANALYSIS OF 450 IMPOTENT PATIENTS TREATED WITH INJECTION THERAPY: LONG-TERM DROPOUT PARAMETERS
- 1 February 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 163 (2) , 467-470
- https://doi.org/10.1016/s0022-5347(05)67902-5
Abstract
Purpose: We report the dropout rate associated with intracavernosal self-injection for erectile dysfunction at long-term followup, and determine parameters related to dropout. Materials and Methods: Of 2,252 impotent patients evaluated during 9 years 450 (20%) enrolled in our self-injection program. Papaverine and phentolamine were given in 53% (initial treatment), prostaglandin E1 in 21%, and papaverine, phentolamine and prostaglandin E1 (triple mixture) in 26% of cases. Average injection volume for the 3 injection types was 0.52 cc. Data were retrospectively reviewed for patient dropout versus nondropout, specifically for type of drug, volume injected, changing treatment (from 1 drug and/or dosage to another), patient age, marital status, ethnic group, impotence duration and diabetes. Results: Patient age ranged from 23 to 79 years (mean age 55). Of the patients treated at least 4 months 155 (35%) dropped out of the study. Mean treatment duration was 3.5 years. Logistic regression suggested that type of drug, changing treatment during the course of therapy and dosage (volume injected) were the only significant (p <0.05) parameters influencing dropout. Papaverine and phentolamine were twice as likely to lead to dropout as triple mixture or prostaglandin E1, and injection greater than 0.5 cc was more than twice as likely to lead to dropout. Demographic, ethnic, age and etiological factors had no significant effect on the overall dropout rate. Conclusions: The effectiveness of injection therapy was an underlying factor determining the long-term dropout rate for patients with erectile dysfunction. Other parameters or combinations of parameters that may influence patient dropout remain to be explored.Keywords
This publication has 11 references indexed in Scilit:
- Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil)Urology, 1999
- Use of Sildenafil (Viagra) in Patients With Cardiovascular DiseaseCirculation, 1999
- DISAPPOINTING INITIAL RESULTS WITH TRANSURETHRAL ALPROSTADIL FOR ERECTILE DYSFUNCTION IN A UROLOGY PRACTICE SETTINGJournal of Urology, 1998
- Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 1998
- COMPARISON OF LONG-TERM OUTCOMES OF PENILE PROSTHESES AND INTRACAVERNOSAL INJECTION THERAPYJournal of Urology, 1998
- Long-term follow-up of patients receiving injection therapy for erectile dysfunctionUrology, 1997
- Predictors of Success and Risk Factors for Attrition in the Use of Intracavernous InjectionJournal of Urology, 1997
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionNew England Journal of Medicine, 1996
- Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotenceUrology, 1993
- Patient satisfaction with pharmacologic erection programUrology, 1992